A systematic comparison of the impact of inflammatory signaling on absorption, distribution, metabolism, and excretion gene expression and activity in primary human hepatocytes and HepaRG Cells

Drug Metabolism and Disposition

Volumn 43, Issue 2, 2015, Pages 273-283

  Klein, Marcus ^a,b   Thomas, Maria ^a,b   Hofmann, Ute ^a,b   Seehofer, Daniel ^c   Damm, Georg ^c   Zanger, Ulrich M ^a,b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; ANTIPORTER; CYTOCHROME P450; IL6 PROTEIN, HUMAN; ISOPROTEIN;

ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DMET GENE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEPARG CELL; HUMAN; HUMAN CELL; INFLAMMATORY SIGNALING; LIQUID CHROMATOGRAPHY; LIVER CELL; LIVER CELL CULTURE; MALE; MIDDLE AGED; PRIMARY CELL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; TANDEM MASS SPECTROMETRY; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DOWN REGULATION; DRUG SCREENING; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; REPRODUCIBILITY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR CELL LINE; YOUNG ADULT;

ADULT; AGED; ANTIPORTERS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME SYSTEM; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; FEMALE; GENE EXPRESSION PROFILING; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HEPATOCYTES; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PROTEIN ISOFORMS; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84921038448     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.060962     Document Type: Article

References (45)

1. Aitken AE and Morgan ET (2007) Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 35: 1687-1693.
2. Aitken AE, Richardson TA, and Morgan ET (2006) Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46:123-149.
3. Andersson TB, Kanebratt KP, and Kenna JG (2012) The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human. Expert Opin Drug Metab Toxicol 8:909-920.
4. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouët S, Morel F, Guguen-Guillouzo C, and Guillouzo A (2006) Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34:75-83.
5. Aninat C, Seguin P, Descheemaeker P-N, Morel F, Malledant Y, and Guillouzo A (2008) Catecholamines induce an inflammatory response in human hepatocytes. Crit Care Med 36: 848-854.
6. Aubert J, Begriche K, Knockaert L, Robin MA, and Fromenty B (2011) Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol 35:630-637.
7. Bachour-El Azzi P, Sharanek A, Abdel-Razzak Z, Antherieu S, Al-Attrache H, Savary CC, Lepage S, Morel I, Labbe G, and Guguen-Guillouzo C,, et al. (2014) Impact of inflammation on chlorpromazine-induced cytotoxicity and cholestatic features in HepaRG cells. Drug Metab Dispos 42:1556-1566.
8. Cerec V, Glaise D, Garnier D, Morosan S, Turlin B, Drenou B, Gripon P, Kremsdorf D, Guguen-Guillouzo C, and Corlu A (2007) Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45:957-967.
9. Cherrington NJ, Estrada TE, Frisk HA, Canet MJ, Hardwick RN, Dvorak B, Lux K, and Halpern MD (2013) The hepatic bile acid transporters Ntcp and Mrp2 are downregulated in experimental necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 304:G48-G56.
10. Congiu M, Mashford ML, Slavin JL, and Desmond PV (2002) UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos 30:129-134.
11. Dickmann LJ, Patel SK, Rock DA, Wienkers LC, and Slatter JG (2011) Effects of interleukin 6 (IL-6) and an anti-IL-6 monoclonal antibody on drug metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos 39:1415-1422.
12. Dickmann LJ, Patel SK, Wienkers LC, and Slatter JG (2012) Effects of interleukin 1b (IL-1b) and IL-1b/interleukin 6 (IL-6) combinations on drug metabolizing enzymes in human hepatocyte culture. Curr Drug Metab 13:930-937.
13. Feidt DM, Klein K, Hofmann U, Riedmaier S, Knobeloch D, Thasler WE, Weiss TS, Schwab M, and Zanger UM (2010) Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes. Drug Metab Dispos 38:1589-1597.
14. Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, Bode JG, Bolleyn J, Borner C, and Böttger J,, et al. (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87: 1315-1530.
15. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, and Guguen-Guillouzo C (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 99:15655-15660.
16. Hakkola J, Hu Y, and Ingelman-Sundberg M (2003) Mechanisms of down-regulation of CYP2E1 expression by inflammatory cytokines in rat hepatoma cells. J Pharmacol Exp Ther 304: 1048-1054.
17. Hart SN, Li Y, Nakamoto K, Subileau EA, Steen D, and Zhong XB (2010) A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab Dispos 38:988-994.
18. Jones SA, Scheller J, and Rose-John S (2011) Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 121:3375-3383.
19. Jover R, Bort R, Gómez-Lechón MJ, and Castell JV (2002) Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J 16:1799-1801.
20. Kanebratt KP and Andersson TB (2008) Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 36:1444-1452.
21. Kim MS, Shigenaga J, Moser A, Feingold K, and Grunfeld C (2003) Repression of farnesoid X receptor during the acute phase response. J Biol Chem 278:8988-8995.
22. Le Hegarat L, Dumont J, Josse R, Huet S, Lanceleur R, Mourot A, Poul J-M, Guguen-Guillouzo C, Guillouzo A, and Fessard V (2010) Assessment of the genotoxic potential of indirect chemical mutagens in HepaRG cells by the comet and the cytokinesis-block micronucleus assays. Mutagenesis 25:555-560.
23. Le Vee M, Gripon P, Stieger B, and Fardel O (2008) Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta. Drug Metab Dispos 36:217-222.
24. Lecluyse EL and Alexandre E (2010) Isolation and culture of primary hepatocytes from resected human liver tissue. Methods Mol Biol 640:57-82.
25. Lee SML, Schelcher C, Demmel M, Hauner M, and Thasler WE (2013) Isolation of human hepatocytes by a two-step collagenase perfusion procedure. J Vis Exp DOI: 10. 3791/50615.
26. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408.
27. Lübberstedt M, Müller-Vieira U, Mayer M, Biemel KM, Knöspel F, Knobeloch D, Nüssler AK, Gerlach JC, and Zeilinger K (2011) HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. J Pharmacol Toxicol Methods 63:59-68.
28. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, and Liddle C,, et al. (2008) Regulation of drugmetabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 36:205-216.
29. Parent R, Marion M-J, Furio L, Trépo C, and Petit M-A (2004) Origin and characterization of a human bipotent liver progenitor cell line. Gastroenterology 126:1147-1156.
30. Petrovic V, Teng S, and Piquette-Miller M (2007) Regulation of drug transporters during infection and inflammation. Mol Interv 7:99-111.
31. Poller B, Drewe J, Krähenbühl S, Huwyler J, and Gutmann H (2010) Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Cell Mol Neurobiol 30:63-70.
32. Renton KW (2005) Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol 1:629-640.
33. Richardson TA, Sherman M, Kalman D, and Morgan ET (2006) Expression of UDPglucuronosyltransferase isoform mRNAs during inflammation and infection in mouse liver and kidney. Drug Metab Dispos 34:351-353.
34. Rogue A, Lambert C, Spire C, Claude N, and Guillouzo A (2012) Interindividual variability in gene expression profiles in human hepatocytes and comparison with HepaRG cells. Drug Metab Dispos 40:151-158.
35. Rose-John S (2012) IL-6 trans-signaling via the soluble IL-6 receptor: importance for the proinflammatory activities of IL-6. Int J Biol Sci 8:1237-1247.
36. Rubin K, Janefeldt A, Andersson L, Berke Z, Grime K, and Andersson TB (2015) HepaRG cells as human-relevant in vitro model to study the effects of inflammatory stimuli on cytochrome P450 isoenzymes. Drug Metab Dispos 43:119-125.
37. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, and Hennessy L,, et al. ; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 110:3507-3512.
38. Shimada T, Tsumura F, and Yamazaki H (1999) Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos 27:1274-1280.
39. Siewert E, Bort R, Kluge R, Heinrich PC, Castell J, and Jover R (2000) Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology 32:49-55.
40. Siewert E, Dietrich CG, Lammert F, Heinrich PC, Matern S, Gartung C, and Geier A (2004) Interleukin-6 regulates hepatic transporters during acute-phase response. Biochem Biophys Res Commun 322:232-238.
41. Spurgeon SL, Jones RC, and Ramakrishnan R (2008) High throughput gene expression measurement with real time PCR in a microfluidic dynamic array. PloS One 3:e1662.
42. Sukhai M, Yong A, Kalitsky J, and Piquette-Miller M (2000) Inflammation and interleukin-6 mediate reductions in the hepatic expression and transcription of the mdr1a and mdr1b genes. Mol Cell Biol Res Commun 4:248-256.
43. Teng S and Piquette-Miller M (2005) The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice. J Pharmacol Exp Ther 312:841-848.
44. Turpeinen M, Tolonen A, Chesne C, Guillouzo A, Uusitalo J, and Pelkonen O (2009) Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. Toxicol In Vitro 23: 748-753.
45. Yang Q, Doshi U, Li N, and Li AP (2012) Effects of culture duration on gene expression of P450 isoforms, uptake and efflux transporters in primary hepatocytes cultured in the absence and presence of interleukin-6: implications for experimental design for the evaluation of downregulatory effects of biotherapeutics. Curr Drug Metab 13:938-946.